Breast Cancer and Fractures Study Prompts Revision in Bone-loss-prevention Guidelines

Breast Cancer and Fractures Study Prompts Revision in Bone-loss-prevention Guidelines
A study suggesting that breast cancer patients on aromatase-inhibitors (AIs) are at higher risk of fractures has prompted several international medical associations to revise guidelines aimed at preventing bone loss in these patients. The organizations include the International Osteoporosis Foundation, Cancer and Bone Society, International Expert Group for AIBL, European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, European Calcified Tissue Society, International Menopause Society, and the International Society for Geriatric Oncology (SIOG). Their recommendations can be found in the study “Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer.” It was published online ahead of the print edition of the Journal of Bone Oncology. Women receiving AIs as an adjuvant breast cancer therapy have two to four times the bone loss of women in menopause, a condition that itself increases the risk of fracture, the study said. An adjuvant therapy is one aimed at increasing the effect of another treatment. "While clinical trials have shown an approximately 10%
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.